GB9401090D0
(en)
*
|
1994-01-21 |
1994-03-16 |
Glaxo Lab Sa |
Chemical compounds
|
US6143746A
(en)
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
US6046206A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
|
US6060477A
(en)
*
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
US5874440A
(en)
*
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
US6331543B1
(en)
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
CA2294480C
(en)
|
1997-06-23 |
2008-05-20 |
Queen's University At Kingston |
Microdose therapy of female sexual dysfunction by no, co, and their donors
|
ES2137113B1
(es)
|
1997-07-29 |
2000-09-16 |
Almirall Prodesfarma Sa |
Nuevos derivados de triazolo-piridazinas heterociclicos.
|
US5852035A
(en)
*
|
1997-12-12 |
1998-12-22 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
US5942520A
(en)
*
|
1998-01-27 |
1999-08-24 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
|
US5990117A
(en)
*
|
1998-04-15 |
1999-11-23 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
US6124303A
(en)
*
|
1998-09-11 |
2000-09-26 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
US6451807B1
(en)
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
IL135817A0
(en)
*
|
1999-04-30 |
2001-05-20 |
Lilly Icos Llc |
Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
|
US6613768B1
(en)
|
1999-04-30 |
2003-09-02 |
Lilly Icos Llc |
Treatment of female arousal disorder
|
JP2003505509A
(ja)
*
|
1999-08-03 |
2003-02-12 |
リリー アイコス リミテッド ライアビリティ カンパニー |
β−カルボリン製薬組成物
|
US20040152106A1
(en)
*
|
1999-10-07 |
2004-08-05 |
Robertson Harold A. |
Gene necessary for striatal function, uses thereof, and compounds for modulating same
|
EP1223937A2
(en)
*
|
1999-10-07 |
2002-07-24 |
Novaneuron Inc. |
Gene necessary for striatal function, uses thereof, and compounds for modulating same
|
NZ517324A
(en)
|
1999-10-11 |
2003-09-26 |
Pfizer |
5-(2-substituted-5-heterocyclylsulphonylpyrid-3-YL)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
|
US20050070499A1
(en)
*
|
1999-11-08 |
2005-03-31 |
Pfizer Inc. |
Compounds for the treatment of female sexual dysfunction
|
IL139457A0
(en)
|
1999-11-08 |
2001-11-25 |
Pfizer |
Compounds for the treatment of female sexual dysfunction
|
US6569638B1
(en)
|
2000-03-03 |
2003-05-27 |
Cell Pathways, Inc |
Method for screening compounds for the treatment of neoplasia
|
US6774128B2
(en)
*
|
2000-04-19 |
2004-08-10 |
Johns Hopkins University |
Methods for prevention and treatment of gastrointestinal disorders
|
ATE343388T1
(de)
|
2000-04-19 |
2006-11-15 |
Lilly Icos Llc |
Pde-v hemmer zur behandlung von morbus parkinson
|
DE60121587T2
(de)
|
2000-06-23 |
2007-09-13 |
Lilly Icos Llc, Wilmington |
Zyklische gmp-spezifische phosphodiesteraseinhibitoren
|
MXPA03000887A
(es)
*
|
2000-08-02 |
2004-04-05 |
Lilly Icos Llc |
Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
ES2381862T3
(es)
*
|
2000-09-06 |
2012-06-01 |
Mitsubishi Tanabe Pharma Corporation |
Preparaciones para administración por vía oral
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
MXPA03002909A
(es)
|
2000-10-02 |
2003-09-10 |
Lilly Icos Llc |
Compuestos quimicos.
|
JP2004510773A
(ja)
*
|
2000-10-02 |
2004-04-08 |
リリー アイコス リミテッド ライアビリティ カンパニー |
化学化合物
|
CA2427573C
(en)
|
2000-11-06 |
2008-10-07 |
Lilly Icos Llc |
Indole derivatives as pde5-inhibitors
|
EP1366050B1
(en)
*
|
2000-11-08 |
2005-04-13 |
Lilly Icos LLC |
Condensed pyrazindione derivatives as pde inhibitors
|
WO2002064119A1
(fr)
*
|
2001-02-15 |
2002-08-22 |
Tanabe Seiyaku Co., Ltd. |
Comprimes a dissolution rapide dans la cavite buccale
|
DE10118306A1
(de)
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
|
DE10118305A1
(de)
*
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Zusammensetzungen zur nasalen Applikation
|
WO2002098428A1
(en)
*
|
2001-06-05 |
2002-12-12 |
Lilly Icos Llc |
Tetracyclic compounds as pde5-inhibitors
|
CA2445189C
(en)
|
2001-06-21 |
2009-02-17 |
Lilly Icos Llc |
Carboline derivatives as pdev inhibitors
|
CA2465893A1
(en)
*
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase v inhibitors
|
ES2337887T3
(es)
*
|
2001-12-20 |
2010-04-30 |
Merck Serono Sa |
Derivados de pirrolidina en calidad de moduladores de prostaglandina.
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7550479B2
(en)
*
|
2002-07-31 |
2009-06-23 |
Lilly Icos Llc |
Modified Pictet-Spengler reaction and products prepared therefrom
|
DK1644021T3
(da)
|
2003-06-13 |
2012-10-29 |
Ironwood Pharmaceuticals Inc |
Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
|
EP1804582A4
(en)
*
|
2004-10-28 |
2009-12-09 |
Reddys Lab Ltd Dr |
POLYMORPH SHAPES OF TADALAFIL
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス,インコーポレイティド |
Pde阻害による神経新生の調節
|
EP2314289A1
(en)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
KR20080065704A
(ko)
|
2005-11-09 |
2008-07-14 |
콤비네이토릭스, 인코포레이티드 |
의학적 이상의 치료 방법들, 조성물들, 및 키트들
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
CA2651862A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
JP2009536669A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
アンジオテンシン調節による神経新生
|
US7998971B2
(en)
*
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
US8293489B2
(en)
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
EP2804603A1
(en)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
US20150297601A1
(en)
|
2012-10-05 |
2015-10-22 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
CN104230960B
(zh)
*
|
2013-06-06 |
2017-02-15 |
山东轩竹医药科技有限公司 |
四并环类间变性淋巴瘤激酶抑制剂
|
US20160317542A1
(en)
|
2013-12-09 |
2016-11-03 |
Respira Therapeutics, Inc. |
Pde5 inhibitor powder formulations and methods relating thereto
|
CN104804016B
(zh)
*
|
2014-01-23 |
2017-06-20 |
山东轩竹医药科技有限公司 |
四并环类间变性淋巴瘤激酶抑制剂
|
US10598672B2
(en)
|
2014-02-18 |
2020-03-24 |
Cyrano Therapeutics, Inc. |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
WO2015200177A1
(en)
|
2014-06-23 |
2015-12-30 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
EP3728266A1
(en)
|
2017-12-20 |
2020-10-28 |
Novartis AG |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
AU2019229256A1
(en)
*
|
2018-02-28 |
2020-09-17 |
Ferro Therapeutics, Inc. |
Compounds with ferroptosis inducing activity and methods of their use
|
US11040964B2
(en)
|
2019-02-27 |
2021-06-22 |
Ferro Therapeutics, Inc. |
Compounds and methods of use
|